RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

<<would you surmise that enemem's suggestion (to sell off the low impact platform as a whole) is a viable avenue?>>

If they can find a single company that wants the whole ball-of-wax, maybe, but the overlap between ADHD and pain companies is small. If Cortex got a good offer that allowed them to then fully develop the high-impacts--there's a good chance they'd take it. But they would have no other source of funds for the high impacts for the foreseeable future, so they'd need to get 3+ years of operating money....why would anyone assume this is an easier sell than licensing RD or ADHD separately?



<<As a side, to Prana's credit, they did negotiate a deal with the loyal shareholders, unlike Cor management.>>

This is becoming an urban myth. Prana did a private placement for A$7 million in March 2008, getting some existing investors to buy in. That is not the same as polling all shareholders to see if they'd like to buy some, it is going to your major shareholders and asking if they'd like to buy more. I'm sure Cortex approached its (few) institutional owners and made the same invitation. And do you think Prana would have the same luck with a private placement in March 2009 as they did in March 2008?

I don't think so.

NeuroInvestment